Literature DB >> 30569446

Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.

Anna Gasinska1, Janusz Jaszczynski, Agnieszka Adamczyk, Anna Janecka-Widła, Waclaw Wilk, Anna Cichocka, Andrzej Stelmach.   

Abstract

INTRODUCTION: It has been suggested that the metastatic potential of neoplastic cells can be predicted on the basis of their biological features, including expression of proteins involved in the epithelial to mesenchymal transition (EMT). Therefore, the purpose of this work was to (1) evaluate the expression of EMT markers: ZEB2, vimentin, N-cadherin, TWIST, PTEN, survivin, E-cadherin, Ki-67 and GLUT-1, (2) assess mutation status of two genes: PIK3CA and KRAS, and (3) investigate the potential relationships between the studied biomarkers and clinicopathological factors in clear-cell renal cell carcinoma (ccRCC).
MATERIAL AND METHODS: Tumor tissue samples (embedded in paraffin blocks) from 159 patients undergoing radical nephrectomy were analyzed. Proteins expression was evaluated immunohistochemically. DNA mutations were analyzed on DNA isolated from tumor tissue and amplified by real-time PCR detection using suitable fluorescent labeled TaqMan assays.
RESULTS: One hundred and seven men and 52 women of mean age of 63.1years were enrolled. Fifty four cancers at pTNM stage I-II and 98 at pTNM III-IV stage were diagnosed. There were 30 Fuhrman grade G1, 61 Fuhrman G2, 49 Fuhrman G3 and 19 Fuhrman G4 tumors. A negative correlation between ZEB2 (p = 0.047, r = -0.172) or E-cadherin expression (p = 0.027, r = -0.191) and TNM was observed. Positive association between grade and Ki-67 (p < 0.001), survivin (p < 0.001), vimentin (p < 0.001) immunoreactivity and negative association between TWIST expression (p = 0.029) or PTEN expression (p = 0.013) were found. Ki-67 expression was positively correlated with survivin (p < 0.001, r = 0.617), vimentin (p = 0.001, r = 0.251) and N-cadherin (p = 0,009, r = 0.207) immunoreactivity which can suggest tumor aggressiveness. TWIST was negatively correlated with E-cadherin (p < 0.001, r = -0.284), vimentin (p < 0.001, r = -0.297) and N-cadherin (p < 0.002, r = -0.241). ZEB2 was not associated with ccRCC grade but was negatively correlated with E-cadherin (p = 0.055, r= -0.153) and PTEN (p = 0.006). GLUT-1 expression was inversely linked to E-cadherin expression (p = 0.022, r= -0.182). Mutations in PIK3CA and KRAS genes were not found in any of the studied ccRCC tumors.
CONCLUSIONS: Low-grade tumors showed higher expression of ZEB2 and TWIST proteins than high-grade tumors, which can suggest that EMT in ccRCC begins at early stages of tumor development and, therefore, evaluation of these proteins, together with other biomarkers, may be useful for assessment of the tumor metastatic potential.

Entities:  

Keywords:  EMT; GLUT-1; IHC; KRAS; Ki-67; PIK3CA; PTEN; TWIST; ZEB2; ccRCC; surviving; vimentin

Mesh:

Substances:

Year:  2018        PMID: 30569446     DOI: 10.5603/FHC.a2018.0023

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  8 in total

Review 1.  A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review).

Authors:  Benjamin Genenger; Jay R Perry; Bruce Ashford; Marie Ranson
Journal:  Discov Oncol       Date:  2022-06-06

2.  Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.

Authors:  Maihulan Maimaiti; Shinichi Sakamoto; Yasutaka Yamada; Masahiro Sugiura; Junryo Rii; Nobuyoshi Takeuchi; Yusuke Imamura; Tomomi Furihata; Keisuke Ando; Kosuke Higuchi; Minhui Xu; Tomokazu Sazuka; Kazuyoshi Nakamura; Atsushi Kaneda; Yoshikatsu Kanai; Natasha Kyprianou; Yuzuru Ikehara; Naohiko Anzai; Tomohiko Ichikawa
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

3.  Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.

Authors:  Kosuke Higuchi; Shinichi Sakamoto; Keisuke Ando; Maihulan Maimaiti; Nobushige Takeshita; Kentaro Okunushi; Yoshie Reien; Yusuke Imamura; Tomokazu Sazuka; Kazuyoshi Nakamura; Jun Matsushima; Tomomi Furihata; Yuzuru Ikehara; Tomohiko Ichikawa; Naohiko Anzai
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

Review 4.  PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.

Authors:  Ali Alqahtani; Hazem S K Ayesh; Hafez Halawani
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

Review 5.  Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.

Authors:  Eva Parisi; Anabel Sorolla; Robert Montal; Rita González-Resina; Anna Novell; Antonieta Salud; Maria Alba Sorolla
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

6.  Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach.

Authors:  Dumitru A Iacobas; Victoria E Mgbemena; Sanda Iacobas; Kareena M Menezes; Huichen Wang; Premkumar B Saganti
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

7.  Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments.

Authors:  Zan He; Zijuan Xin; Qiong Yang; Chen Wang; Meng Li; Wei Rao; Zhimin Du; Jia Bai; Zixuan Guo; Xiuyan Ruan; Zhaojun Zhang; Xiangdong Fang; Hua Zhao
Journal:  Elife       Date:  2022-07-27       Impact factor: 8.713

8.  Circular RNA microarray expression profile and potential function of circ0005875 in clear cell renal cell carcinoma.

Authors:  Qi Lv; Chunhui Ma; Haoming Li; Xuefeng Tan; Gangmin Wang; Yinan Zhang; Peijun Wang
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.